PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brheartjLink to Publisher's site
 
Br Heart J. 1987 January; 57(1): 28–31.
PMCID: PMC1277142

Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo.

Abstract

Body temperature was studied in 65 patients admitted to hospital within four hours of the onset of symptoms of acute myocardial infarction. Thirty three patients had been randomly assigned to intravenous timolol treatment and 32 to placebo treatment. Infarct evolution was assessed by continuous vectorcardiography and creatine kinase release. Maximum and mean temperatures during the first eight days were significantly lower in the timolol group, who were discharged from hospital one day earlier. Eight patients in the placebo group had temperatures of greater than 39 degrees compared with one in the timolol group. Both the mean temperature and the maximum temperature correlated significantly with indices of infarct size and ischaemic area as estimated by cumulative creatine kinase release, QRS vector difference, and ST vector magnitude. The results were consistent with the view that reduction of infarct size may partly explain the reduced pyrexial response after timolol treatment. Other mechanisms are probably also involved in larger infarcts. Because high fever has detrimental haemodynamic effects in acute myocardial infarction, reduction of this response may be beneficial. The results support the early use of beta adrenoceptor blockade in acute myocardial infarction.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (615K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Risøe C, Kirkeby OJ. Reduction of the pyrexial response to acute myocardial infarction by beta-adrenoceptor blockade. Acta Med Scand. 1986;219(3):271–274. [PubMed]
  • Shell WE, Kjekshus JK, Sobel BE. Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest. 1971 Dec;50(12):2614–2625. [PMC free article] [PubMed]
  • Sederholm M, Grøttum P, Erhardt L, Kjekshus J. Quantitative assessment of myocardial ischemia and necrosis by continuous vectorcardiography and measurement of creatine kinase release in patients. Circulation. 1983 Nov;68(5):1006–1012. [PubMed]
  • Atkins E. Fever--new perspectives on an old phenomenon. N Engl J Med. 1983 Apr 21;308(16):958–969. [PubMed]
  • Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med. 1983 Mar 10;308(10):553–558. [PubMed]
  • Fitzsimons EJ, Kaplan K. Rapid drop in serum iron concentration in myocardial infarction. Am J Clin Pathol. 1980 Apr;73(4):552–555. [PubMed]
  • Ksiazek A, Kleinrok Z. The central action of beta-adrenergic receptor blocking agents. I. The central action of intraventricularly administered isoprenaline in the rat. Pol J Pharmacol Pharm. 1974 May-Jun;26(3):287–295. [PubMed]
  • Welle SL, Thompson DA, Campbell RG. Beta-adrenergic blockade inhibits thermogenesis and lipolysis during glucoprivation in humans. Am J Physiol. 1982 Sep;243(3):R379–R382. [PubMed]
  • Abdullah AK, Goel JK, Siddiqui MA. Systolic time intervals in febrile states. Jpn Heart J. 1981 Sep;22(5):739–745. [PubMed]
  • Friman G, Wright JE, Ilbäck NG, Beisel WR, White JD, Sharp DS, Stephen EL, Daniels WL, Vogel JA. Does fever or myalgia indicate reduced physical performance capacity in viral infections? Acta Med Scand. 1985;217(4):353–361. [PubMed]
  • Friman G. Effects of acute infectious disease on circulatory function. Acta Med Scand Suppl. 1976;592:1–62. [PubMed]
  • Herlitz J, Hartford M, Pennert K, Waagstein F, Waldenström A, Wedel H, Wilhelmsson C, Hjalmarson A. Göteborg Metoprolol Trial: clinical observations. Am J Cardiol. 1984 Jun 25;53(13):37D–45D. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Group